Published by: Michael Bedecs The news last week that some big box chain stores are jumping on the “weight loss bandwagon” and offering semaglutide is troubling. We’re fully in favor of making this life-changing medication accessible to those who medically qualify,...
Published by: Age Management Center “In the U.S., an estimated 6,000 women daily and more than 2 million women yearly reach menopause. With an average life expectancy of 81, women are spending greater than one-third of their lives in menopause.” Mayo Clinic Menopause...
For anyone that didn’t catch Oprah’s recent TV special "Shame, blame and the weight loss revolution”, we hope that you can take time to find it on Hulu or ABC, because there are so many powerful stories and messages that we wish our clients, and those considering...
Published by: Age Management Center Recently, The Lancet published a series highlighting concerns about the over-medicalization of menopause, sparking discussions about the treatment approaches for this transitional phase in a woman's life. While we wholeheartedly...
Every woman’s journey through hormone replacement therapy (HRT) is unique and we believe that women should have the freedom to choose the HRT method that aligns with their preferences and lifestyle. That’s why we proudly offer a range of options, including...
Last month I had the opportunity to attend the annual Age Management Medicine Group (AMMG) Conference in Florida. This national conference is aimed at bringing together top thought leaders and specialists in the Age Management sphere to discuss the latest research, innovations and advancements in our field of medicine. As always, the breadth and extent of presentations was stimulating and thought-provoking.
In the coming weeks I will be sharing a number of interesting takeaways from the conference, but to begin, I’d like to cover a topic that has caused much fear and confusion for decades: testosterone and prostate cancer.
Men can be wary of the risk testosterone therapies may have on their health, in particular, the risk of cancer. Since the 1940s, the medical community has relied on what we now know to be outdated research that implied testosterone therapies could potentially increase the risk of prostate cancer.
During his lecture, “Lessons from the Past, A View to the Future — Can We Now Offer Testosterone Therapy to Men with Prostate Cancer?” Dr. Abraham Morgentaler, MD, President of The Androgen Society and Associate Clinical Professor of Urology at Harvard Medical School, took us through a detailed medical analysis of the risks—or lack thereof—of testosterone treatment and prostate cancer. He began the lecture by stating, “nearly everything we learned about testosterone and prostate cancer turned out to be wrong!”
Throughout the course of his lecture, he revealed that “the general rule that ‘cancer of the prostate is activated by testosterone injections’ was based on a single non-castrated patient.”
According to the research he presented, prohibiting testosterone therapies in men with prostate cancer is based on weak evidence that wasn’t challenged or re-examined for decades, and in fact, testosterone therapies in t-deficient men may offer a variety of benefits.
His takeaways?
For men interested in testosterone replacement therapy, but that still have concerns about whether it might be right for you, give us a call to chat more about your specific questions and health concerns. Remember, our initial screening is always free and we’re here to help you get back to feeling optimal and to living as well as you can for as long as you can.
